Modified proteins as vaccines against peach allergy

January 20, 2014, Universidad Politécnica de Madrid
Modified proteins as vaccines against peach allergy

A research conducted by the Centre for Plant Biotechnology and Genomics (UPM-INIA) and led by Araceli Díaz Perales has studied the allergy to peach, the most common food allergy, and the Pru p 3 protein. As a result of this research work, they have developed three hypoallergenic variants of this protein. All can be good candidates for the usage of specific immunotherapy for peach allergy and also can be used as a vaccine.

Nowadays, allergy affects over 25% of the population of developed countries. Currently, the treatment of food allergy consists of avoiding the intake of the food causing the allergy. However, the possibility of cross-reactivity (reaction to related food) might be ineffective.

The specific immunotherapy is the only treatment to prevent more severe signs of allergy progression. Immunotherapy consists of the intake of growing doses of allergen extracts in affected patients. However, the use of this extract could induce anaphylactic reactions or lead to sensitization to new allergens found in the mixture of allergen extracts. According to this, the usage of hypoallergenic molecules (with lower ability of binding antibodies) but with the ability to stimulate the , would be a useful tool for immunotherapy.

The most common in Spain and the Mediterranean areas is the peach allergy which is mainly caused by the Pru p 3 proteins. The current treatment of this allergy consists of avoiding peach consumption, neither fresh nor processed peaches (juices jam). As an alternative, this allergy research has defined the regions of this allergenic that is involved in the antibody binding and the stimulation of the immune system cells. After that, researchers developed three hypoallergenic variants of this protein that can be used as a .

These variants are the result of modifying epitopes (regions of binding antibodies) of this protein and they were used in a research with patient allergic to peach in order to confirm its capacity as immune system stimulation. Each variant has a different modification that was designed by using genetic tools. Although the 1 variant (Pru p 3.01) showed quite similar allergenic activity with the natural protein, the variants Pru p 3.02 and Pru p 3.03 presented lower capacity for binding antibodies. Also, it maintained its ability to stimulate immune system cells (lymphocytes) of the patients allergic to peach during the in vitro trials.

The results show that these two molecules (Pru p 3.02 and Pru p 3.03) could be good candidates for the usage of specific immunotherapy for allergy to peach.

This research work has established the basis to set a new strategy although it would be required further trials of these two molecules with animal to verify its effectiveness in the treatment for allergy to peach.

Explore further: Merck: FDA reviewing tablet to eliminate allergy

More information: "Allergenic Characterization of New Mutant Forms of Pru p 3 as New Immunotherapy Vaccines". Clinical & Developmental Inmunology, Vol. 2013. dx.doi.org/10.1155/2013/385615

Related Stories

Merck: FDA reviewing tablet to eliminate allergy

March 27, 2013
Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that gradually reduces allergy symptoms over time, rather than just temporarily relieving ...

You can have a food allergy, and eat it too

November 8, 2013
Have food allergies? If you answered yes, you know the best way to prevent a severe allergic reaction is to totally avoid the offending food. But according to a presentation at the Annual Scientific Meeting of the American ...

Allergy shots during pregnancy may decrease allergies in children

November 8, 2013
Expecting mothers who suffer from allergies may want to consider another vaccination in addition to the flu shot and Tdap. A study being presented at the Annual Scientific Meeting of the American College of Allergy, Asthma ...

Merck says FDA reviewing its ragweed allergy therapy

May 8, 2013
Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...

Oral allergy syndrome and high blood pressure medications can create lethal cocktail

November 8, 2013
Oral allergy syndrome sufferers that take high blood pressure medications may experience extreme facial swelling and difficulty breathing the next time they bite into a juicy apple. When patients with oral allergy syndrome ...

The great disappearing act: Bone marrow receiver cured of allergy

November 8, 2013
Not only can bone marrow transplants be life-saving for children with acute lymphocytic leukemia, they may also cure peanut allergies. According to research presented during the American College of Allergy, Asthma and Immunology's ...

Recommended for you

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

Researchers identify new way to unmask melanoma cells to the immune system

January 16, 2018
system, which enables these deadly skin cancers to grow and spread.

How the immune system's key organ regenerates itself

January 15, 2018
With advances in cancer immunotherapy splashing across headlines, the immune system's powerful cancer assassins—T cells—have become dinner-table conversation. But hiding in plain sight behind that "T" is the organ from ...

Immunosuppressive cells in newborns play important role in controlling inflammation in early life

January 15, 2018
New research led by The Wistar Institute, in collaboration with Sun Yat-sen University in China, has characterized the transitory presence of myeloid-derived suppressor cells (MDSCs) in mouse and human newborns, revealing ...

Memory loss from West Nile virus may be preventable

January 15, 2018
More than 10,000 people in the United States are living with memory loss and other persistent neurological problems that occur after West Nile virus infects the brain.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.